Research

Journal articles (11)

• Vanderbeek AM, Redd RA, Ventz S, Trippa L. Looking ahead in early-phase trial design to improve the drug development process: examples in oncology. BMC Medical Research Methodology. 2023;23(1):151.
• Pownder SL, Neri JP, Hayashi K, Vanderbeek AM, Koff MF. Age and sex comparison of the canine supraspinatus tendon using quantitative magnetic resonance imaging T2 mapping. Veterinary and Comparative Orthopaedics and Traumatology. 2023;36(2):87–92.
• Tan ET, Serrano KC, Bhatti P, Pishgar F, Vanderbeek AM, Milani CJ, Sneag DB. Quantitative MRI differentiates electromyography severity grades of denervated muscle in neuropathy of the brachial plexus. Journal of Magnetic Resonance Imaging. 2022;56(4):1104–1115.
• Lai-Kwon J, Vanderbeek AM, Minchom A, Aiyegbusi OL, Ogunleye D, Stephens R, Calvert M, Yap C. Using patient-reported outcomes in dose-finding oncology trials: surveys of key stakeholders and the National Cancer Research Institute Consumer Forum. The Oncologist. 2022;27(9):768–777.
• Shea S, Thompson JLP, Schwartz JE, Chen Y, de Ferrante M, Vanderbeek AM, Buchsbaum R, Vargas C, Siddiqui KM, Moran AE, Stockwell M. The retail outlet health kiosk hypertension trial (ROKHYT): pilot results. American Journal of Hypertension. 2022;35(1):103–110.
• Vanderbeek AM, Bliss JM, Yin Z, Yap C. Implementation of platform trials in the COVID-19 pandemic: a rapid review. Contemporary Clinical Trials. 2022;112:106625.
• Fell G, Redd RA, Vanderbeek AM, Rahman R, Louv B, McDunn J, Arfè A, Alexander BM, Ventz S, Trippa L. KMDATA: a curated database of reconstructed individual patient-level data from 153 oncology clinical trials. Database. 2021;2021:baab037.
• Rahman R, Fell G, Ventz S, Arfè A, Vanderbeek AM, Trippa L, Alexander BM. Deviation from the proportional hazards assumption in randomized phase 3 clinical trials in oncology: prevalence, associated factors, and implications. Clinical Cancer Research. 2019;25(21):6339–6345.
• Vanderbeek AM, Ventz S, Rahman R, Fell G, Cloughesy TF, Wen PY, Trippa L, Alexander BM. To randomize, or not to randomize, that is the question: using data from prior clinical trials to guide future designs. Neuro-Oncology. 2019;21(10):1239–1249.
• Rahman R, Ventz S, Fell G, Vanderbeek AM, Trippa L, Alexander BM. Divining responder populations from survival data. Annals of Oncology. 2019;30(6):1005–1013.
• Vanderbeek AM, Rahman R, Fell G, Ventz S, Chen T, Redd R, Parmigiani G, Cloughesy TF, Wen PY, Trippa L, Alexander BM. The clinical trials landscape for glioblastoma: is it adequate to develop new treatments? Neuro-Oncology. 2018;20(8):1034–1043.

Preprints (3)

• Vanderbeek AM, Sabbaghi A, Walsh JR, Fisher CK. Bayesian prognostic covariate adjustment with additive mixture priors. arXiv:2310.18027. 2023.
• Vanderbeek AM, Vidovszky AA, Ross JL, Sabbaghi A, Walsh JR, Fisher CK, Alzheimer’s Disease Neuroimaging Initiative. A weighted prognostic covariate adjustment method for efficient and powerful treatment effect inferences in randomized controlled trials. arXiv:2309.14256. 2023.
• Vanderbeek AM, Ross JL, Miller DP, Schuler A. Prognostic covariate adjustment for binary outcomes using stratification. arXiv:2212.09903. 2022.

Conference posters (1)

• To randomize or not to randomize? 3rd Annual Stat4Onc Conference, May 2019.

Conference abstracts (4)

• Pedrick E, Sneag DB, Colucci PG, Duong M, Vanderbeek A, Tan ET. Low-dose ferumoxytol infusion provides effective vascular suppression for magnetic resonance neurography. ISMRM Annual Meeting. 2022.
• Jardon M, Tan ET, Chazen JL, Sahr M, Wen Y, Vanderbeek AM, Sneag DB. Evaluation of deep-learning reconstructed high-resolution 3D cervical spine MRI to improve foraminal stenosis evaluation. ISMRM Annual Meeting. 2022.
• Lai-Kwon JE, Vanderbeek A, Minchom A, Yap C. Using patient-reported outcomes (PROs) in dose-finding oncology trials (DFOT): results from a global stakeholder survey and the National Cancer Research Institute (NCRI). Annals of Oncology. 2021;32:S589.
• Lai-Kwon JE, Vanderbeek A, Minchom A, Yap C. Using patient-reported outcomes (PROs) in phase I/II dose-finding oncology trials (DPOT): a global survey. Annals of Oncology. 2021;32:S17.

Talks and panels (7)

• Digital twins in clinical trials: how they work, and how they don’t. 2025 Design and Management of Cancer Clinical Trials Course (six-week CME course for physicians and clinical researchers), University of Miami Miller School of Medicine (virtual), October 2025.
• Benefits and challenges of AI in clinical research (panelist). 2025 Design and Management of Cancer Clinical Trials Course, University of Miami Miller School of Medicine (virtual), October 2025.
• PROCOVA-CMH: Prognostic covariate adjustment for binary outcomes with stratification. Joint Statistical Meetings, August 2023.
• Implementation of platform trials in the COVID-19 pandemic: a rapid review. 42nd Annual Conference of the International Society for Clinical Biostatistics (virtual), July 2021.
• Consequences of Phase I Dose Selection on Go/No-Go Decisions in Oncology Drug Development. Society for Clinical Trials Annual Meeting (virtual), May 2021.
• Platform trials take the spotlight in COVID-19. Society for Clinical Trials Annual Meeting (virtual), May 2021.
• iAdapt: an R package and Shiny app for simulation and implementation of early phase dose-finding designs incorporating toxicity and continuous efficacy outcomes. ASA Conference on Statistical Practice, February 2020.

Software (1)

• iAdapt: Two-Stage Adaptive Dose-Finding Clinical Trial Design. R package, v2.0.1 (first published 2019).